Takeda, Eisai To Speed Cancer Drugs From Acquisitions
This article was originally published in PharmAsia News
Executive Summary
Japanese drug makers Takeda Pharmaceutical and Eisai plan to take advantage of recent U.S. acquisitions to step up development of cancer drugs. Both firms gained access to the drugs with buys this year, Takeda with Millennium Pharmaceuticals, Eisai with MGI Pharma. Takeda plans to begin Phase II trials for its candidate this year while Eisai begins trials on a compound similar to Takeda's, for inhibiting cancer growth. In addition, Eisai is gearing up for a planned three-year expansion to quintuple that aspect of its business. (Click here for more - a subscription may be required
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.